Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Research Foundation of Korea | OTHER |
Not provided
Not provided
Not provided
The aim of this study is to evaluate the efficacy of early metabolic resuscitation with combination therapy using vitamin C and thiamine in improving organ function and survival in patients with septic shock.
Sepsis is a complex disease involving life-threatening organ dysfunction caused by a dysregulated host response to infection and is still associated with unacceptably high mortality. Sepsis management should be undertaken as a medical emergency and focused on timely intervention, including early identification and treatment of infection through appropriate antimicrobial therapy and source control when applicable as well as reversing hemodynamic instability through fluid resuscitation and vasopressor use if necessary. Despite these supportive therapies, morbidity and mortality have remained high, suggesting the need for adjuvant therapies for inflammatory and oxidative stress in patients with sepsis; however, no agents have been proven to definitely improve survival.
Vitamin C plays a role in mediating inflammation through antioxidant activities and is also important as a cofactor/co-substrate for the synthesis of endogenous adrenaline, cortisol, and vasopressin. Recently, several clinical trials have reported the positive effects of vitamin C on outcomes in sepsis or septic shock. During sepsis, vitamin C prevents neutrophil-induced lipid oxidation and protects against the loss of the endothelial barrier. Early intravenous supplementation is therefore needed to limit loss of microcirculation and oxidation of lipids. Thiamine is also a key cofactor for glucose metabolism, the generation of ATP (adenosine triphosphate), and the production of NADPH. Considering acute consumption in the hypermetabolic state, thiamine supplementation might be a reasonable therapeutic adjunct for patients with sepsis and was added to reduce the risk of renal oxalate crystallization. These findings led to a recent before-and-after study showing that treatment of sepsis with a combination of vitamin C, hydrocortisone, and thiamine prevented organ dysfunction and reduced the mortality rate.
The aim of this study is to evaluate the efficacy of early metabolic resuscitation with combination therapy using vitamin C and thiamine in improving organ function and survival in patients with septic shock.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment | Experimental | Combination therapy of vitamin C and thiamine for 2 days. |
|
| Control | Placebo Comparator | Normal Saline Solution |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Combination therapy of vitamin C and thiamine | Drug | Vitamin C (50 mg/kg up to 3 g, every 12 hours) and thiamine (200 mg every 12 hours) intravenously administered mixed in 50 mL solution bags of normal saline for 2 days |
| Measure | Description | Time Frame |
|---|---|---|
| Delta Sequential Organ Failure Assessment (SOFA) score | 72-hour change in SOFA score, which reflected recovery from organ failure (delta SOFA = SOFA at enrollment - SOFA after 72 hours) | Enrollment to 72 hours |
| Measure | Description | Time Frame |
|---|---|---|
| 28-day mortality | The number of participants who did not survive until Day 28 will be compared between the treatment and the control group | Day 28 |
| 7-day mortality (early death) | The number of participants who did not survive until Day 7 will be compared between the treatment and the control group |
| Measure | Description | Time Frame |
|---|---|---|
| CRP (C-reactive protein) change during initial 72 hours | 72-hour change in CRP (%) | Enrollment to 72 hours |
| Procalcitonin change during initial 72 hours | 72-hour change in procalcitonin (%) |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Tae Gun Shin, MD, PhD | Samsung Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Emergency Medicine, Seoul National University Bundang Hospital, | Seongnam-si | Gyeonggi-do | South Korea | |||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 26903338 | Background | Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287. | |
| 28098591 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012772 | Shock, Septic |
| D018805 | Sepsis |
| ID | Term |
|---|---|
| D007239 | Infections |
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |
| D010335 | Pathologic Processes |
Not provided
Not provided
| ID | Term |
|---|---|
| D013831 | Thiamine |
| D001205 | Ascorbic Acid |
| D000077330 | Saline Solution |
| ID | Term |
|---|---|
| D013844 | Thiazoles |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
| D001393 | Azoles |
Not provided
Not provided
Multi-center, Double-blinded, Randomized, Controlled Study
Not provided
Not provided
Not provided
|
| Normal saline solution | Drug | Normal saline solution in a volume to match the treatment components administered mixed in 50 mL solution bags of normal saline for 2 days |
|
|
| Day 7 |
| 90-day mortality | The number of participants who did not survive until Day 90 will be compared between the treatment and the control group | Day 90 |
| Time to death | Days until death | Enrollment to Day 28 |
| In-hospital death | The number of participants who did not survive at hospital discharge will be compared between the treatment and the control group | Up to 12 weeks |
| Intensive care unit death (ICU) death | The number of participants who did not survive at ICU discharge from the first index ICU admission will be compared between the treatment and the control group | Up to 12 weeks |
| Time to Shock reversal | Days from enrollment to shock reversal until Day 14. Shock reversal is defined as discontinuation of all vasopressors and mean arterial pressure is maintained at 60 mmHg or more for more than 24 hours. | Enrollment to Day 14 |
| Vasopressor free days | Days not receiving any vasopressor | Enrollment to Day 14 |
| Ventilator free days | Days not receiving mechanical ventilation | Enrollment to Day 14 |
| Ventilator duration | Days receiving mechanical ventilation during hospital stay | Up to 12 weeks |
| Renal replacement therapy (RRT) free days | Days not receiving Renal replacement therapy | Enrollment to Day 14 |
| New use of renal replacement therapy (RRT) | The number of participants who receive RRT during hospital stay will be compared between the treatment and the control group | Up to 12 weeks |
| New onset or aggravation of acute kidney injury (AKI) | The number of participants who suffer from new onset or aggravation of AKI will be compared between the treatment and the control group | Enrollment to Day 14 |
| Length of ICU stay | Number of days in the ICU during hospital admission | Up to 12 weeks |
| ICU free day | Days not being in the ICU | Enrollment to Day 14 |
| Length of hospital stay | Number of days in the hospital during hospital admission | Up to 12 weeks |
| Enrollment to 72 hours |
| Dose of vasopressor at 24-hour | Norepinephrine equivalent dose at 24 hours from enrollment | Enrollment to 24 hours |
| Dose of vasopressor at 48-hour | Norepinephrine equivalent dose at 48 hours from enrollment | Enrollment to 48 hours |
| Dose of vasopressor at 72-hour | Norepinephrine equivalent dose at 72 hours from enrollment | Enrollment to 72 hours |
| Maximum dose of vasopressor during initial 72 hours | Maximum norepinephrine equivalent dose during initial 72 hours | Enrollment to 72 hours |
| Department of Emergency Medicine, Borame Medical Center, Seoul National University, College of Medicine |
| Seoul |
| South Korea |
| Department of Emergency Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, | Seoul | South Korea |
| Department of Emergency Medicine, Seoul National University College of Medicine, | Seoul | South Korea |
| Department of Emergency Medicine, University of Ulsan College of Medicine, Asan Medical Center, | Seoul | South Korea |
| Department of Emergency Medicine, Yonsei University College of Medicine | Seoul | South Korea |
| Background |
| Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Crit Care Med. 2017 Mar;45(3):486-552. doi: 10.1097/CCM.0000000000002255. |
| 28934705 | Background | Teng J, Pourmand A, Mazer-Amirshahi M. Vitamin C: The next step in sepsis management? J Crit Care. 2018 Feb;43:230-234. doi: 10.1016/j.jcrc.2017.09.031. Epub 2017 Sep 18. |
| 27940189 | Background | Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study. Chest. 2017 Jun;151(6):1229-1238. doi: 10.1016/j.chest.2016.11.036. Epub 2016 Dec 6. |
| 25185110 | Background | Oudemans-van Straaten HM, Spoelstra-de Man AM, de Waard MC. Vitamin C revisited. Crit Care. 2014 Aug 6;18(4):460. doi: 10.1186/s13054-014-0460-x. |
| 26771781 | Background | Donnino MW, Andersen LW, Chase M, Berg KM, Tidswell M, Giberson T, Wolfe R, Moskowitz A, Smithline H, Ngo L, Cocchi MN; Center for Resuscitation Science Research Group. Randomized, Double-Blind, Placebo-Controlled Trial of Thiamine as a Metabolic Resuscitator in Septic Shock: A Pilot Study. Crit Care Med. 2016 Feb;44(2):360-7. doi: 10.1097/CCM.0000000000001572. |
| 27162802 | Background | Zabet MH, Mohammadi M, Ramezani M, Khalili H. Effect of high-dose Ascorbic acid on vasopressor's requirement in septic shock. J Res Pharm Pract. 2016 Apr-Jun;5(2):94-100. doi: 10.4103/2279-042X.179569. |
| 24484547 | Background | Fowler AA 3rd, Syed AA, Knowlson S, Sculthorpe R, Farthing D, DeWilde C, Farthing CA, Larus TL, Martin E, Brophy DF, Gupta S; Medical Respiratory Intensive Care Unit Nursing; Fisher BJ, Natarajan R. Phase I safety trial of intravenous ascorbic acid in patients with severe sepsis. J Transl Med. 2014 Jan 31;12:32. doi: 10.1186/1479-5876-12-32. |
| 23581713 | Background | May JM, Harrison FE. Role of vitamin C in the function of the vascular endothelium. Antioxid Redox Signal. 2013 Dec 10;19(17):2068-83. doi: 10.1089/ars.2013.5205. Epub 2013 May 29. |
| 27501325 | Background | Leite HP, de Lima LF. Metabolic resuscitation in sepsis: a necessary step beyond the hemodynamic? J Thorac Dis. 2016 Jul;8(7):E552-7. doi: 10.21037/jtd.2016.05.37. |
| 28231816 | Background | de Grooth HJ, Geenen IL, Girbes AR, Vincent JL, Parienti JJ, Oudemans-van Straaten HM. SOFA and mortality endpoints in randomized controlled trials: a systematic review and meta-regression analysis. Crit Care. 2017 Feb 24;21(1):38. doi: 10.1186/s13054-017-1609-1. |
| 34482319 | Derived | Park JE, Jo YH, Hwang SY, Kim WY, Ryoo SM, Jang DH, Kim T, Kim YJ, Kim S, Cho H, Lee GT, Chung SP, Choi SH, Shin TG, Suh GJ; Korean Shock Society (KoSS) Investigators. Biomarker Analysis for Combination Therapy of Vitamin C and Thiamine in Septic Shock: A Post-Hoc Study of the ATESS Trial. Shock. 2022 Jan 1;57(1):81-87. doi: 10.1097/SHK.0000000000001850. |
| 31296251 | Derived | Hwang SY, Park JE, Jo IJ, Kim S, Chung SP, Kong T, Shin J, Lee HJ, You KM, Jo YH, Kim D, Suh GJ, Kim T, Kim WY, Kim YJ, Ryoo SM, Choi SH, Shin TG; Korean Shock Society (KoSS) Investigators. Combination therapy of vitamin C and thiamine for septic shock in a multicentre, double-blind, randomized, controlled study (ATESS): study protocol for a randomized controlled trial. Trials. 2019 Jul 11;20(1):420. doi: 10.1186/s13063-019-3542-x. |
| D013568 |
| Pathological Conditions, Signs and Symptoms |
| D012769 | Shock |
| D006573 |
| Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D011743 | Pyrimidines |
| D013400 | Sugar Acids |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D006880 | Hydroxy Acids |
| D002241 | Carbohydrates |
| D000077324 | Crystalloid Solutions |
| D007552 | Isotonic Solutions |
| D012996 | Solutions |
| D004364 | Pharmaceutical Preparations |